R-CHOP + acalabrutinib
Small molecule
R-CHOP + acalabrutinib is one of 42 small molecule programs targeting Diffuse Large B-Cell Lymphoma. It is currently in development.
1
Indications
2
Total Trials
1
Active Trials
41
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
332 competitors in Diffuse Large B-Cell Lymphoma
#DrugCompanyPhaseTrials
1Rituxan
RochePhase 3
Eloxatin
TevaPhase 3
Rayos
RRoxane Laboratories
Phase 3
Revlimid
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 3
COLUMVI
RochePhase 3
Cytosar
TevaPhase 3
Vepesid
AAvyxa
Phase 3
Adriamycin
GGynecologic Oncology Group
Phase 3
Imbruvica
PPharmacyclics LLC.
Phase 3
Oncovin
EEastern Cooperative Oncology Group
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Diffuse Large B-Cell Lymphoma2 trials
Acalabrutinib in Combination With R-CHOP for Previously Untreated Diffuse Large B-cell Lymphoma (DLBCL)
Active, not recruiting·UUniversity Hospital Southampton NHS Foundation Trust·Phase 2·NCT04546620·453 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for R-CHOP + acalabrutinib. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]